September 11, 2008 – Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced that it has submitted an application to the European Medicines Agency (EMEA) to license Erbitux® (cetuximab) for the first-line treatment of epidermal growth factor receptor (EGFR) expressing, advanced or metastatic non-small cell lung cancer (NSCLC).The submission is supported by data from the Phase III FLEXa study presented this year at the plenary session of the American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrated a significant increase in overall survival for patients receiving Erbitux in combination with a platinum-based chemotherapy as a first-line treatment for advanced NSCLC... [PDF] Merck Serono's Press Release -
